Biocon Biologics Report the P-III Study Positive Results of Yesintek (Biosimilar, Stelara)
Shots:
- Biocon Biologics revealed positive results from the P-III study demonstrating that Yesintek achieved equivalent efficacy, safety, immunogenicity, and PK vs reference product to treat mod. to sev. chronic plaque psoriasis (PsO) pts. (n=384, age= 18-80yrs.); data was presented at AAD 2025
- The primary efficacy endpoint, percentage change in PASI scores at Wk. 12 showed similar improvement, with a mean difference of 0.68%, within predefined equivalence margins of the US FDA & EMA. Switching from Stelara to YESINTEK at Wk. 16 maintained efficacy & safety through Wk. 52
- Yesintek (mAb) targets interleukins IL-12 and IL-23, approved for the treatment of Crohn’s disease, Ulcerative Colitis, PsO and Psoriatic Arthritis
Ref: Prnewswire | Image: Biocon Biologics
Related News:- Biocon Biologics Partners with Civica to extend access of Insulin Aspart in the US
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
A passionate content writer with expertise in delivering high-quality and engaging content, Dipanshu is a keen reader and a versatile writer. Dipanshu dedicatedly covers news ranging from biopharma, life sciences, biotech, and MedTech to diagnostics and animal health companies, FDA, EMA, and biosimilar approvals. He can be contacted at connect@pharmashots.com
